Insulin glargine and lixisenatide and Mogamulizumab-kpkc Intravenous
Determining the interaction of Insulin glargine and lixisenatide and Mogamulizumab-kpkc Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin Glargine and Lixisenatide
Generic Name: mogamulizumab
Brand name: Poteligeo
Synonyms: Mogamulizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide-Molindone
- Insulin glargine and lixisenatide-Mometasone (Oral Inhalation)
- Insulin glargine and lixisenatide-Mometasone and Formoterol
- Insulin glargine and lixisenatide-Mometasone and formoterol Inhalation
- Insulin glargine and lixisenatide-Mometasone Cream
- Insulin glargine and lixisenatide-Mometasone Furoate
- Mogamulizumab-kpkc Intravenous-Insulin glargine and lixisenatide Subcutaneous
- Mogamulizumab-kpkc Intravenous-Insulin glargine, recombinant Subcutaneous
- Mogamulizumab-kpkc Intravenous-Insulin glulisine
- Mogamulizumab-kpkc Intravenous-Insulin Glulisine (Cartridges and Pens)
- Mogamulizumab-kpkc Intravenous-Insulin Glulisine (Vials)
- Mogamulizumab-kpkc Intravenous-Insulin glulisine Subcutaneous